Telix Pharmaceuticals Limited

telixpharma.com

Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic ('theranostic') radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with commercial operations in the United States, Europe (Belgium and Switzerland) and Japan. Telix is developing a portfolio of radiopharmaceutical products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

CYBIN ANNOUNCES ADDITIONAL ADELIA MILESTONE ACHIEVEMENT

Cybin Inc. | January 28, 2022

news image

Cybin Inc. a biotechnology company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that Adelia Therapeutics Inc. a wholly-controlled subsidiary of Cybin, has achieved the milestones identified as Y1, Q4 (iv), Y1, Q4 (v) and Y2, Q1 (vi) as contemplated by the terms of a contribution agreement dated December 4, 2020 among Cybin, Cybin Corp., Cybin US Holdings Inc. a wholly-controlled subsidiary of Cybin, and all of the previous shareholders of Adelia.
Read More

Cell and Gene Therapy

BIODESIX ANNOUNCES SENIOR SECURED FINANCING AGREEMENT WITH PERCEPTIVE ADVISORS FOR UP TO $50 MILLION

Biodesix | November 17, 2022

news image

Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, announced that it has obtained a term loan facility for up to $50 million from Perceptive Advisors, a leading healthcare investment firm focused on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare. This debt capital, which is conditioned on the Company raising at least $30 millio...

Read More

Medical, Industry Outlook

TRIRX PARTNERSHIP WITH LIVERPOOL CITY REGION ADVANCES BIOTECH CAPABILITIES

PRNewswire | July 31, 2023

news image

TriRx Pharmaceutical Services, LLC, a Contract Development and Manufacturing Organization (CDMO), welcomed the UK Government's recent announcement on England's second Investment Zone, focused on Life Sciences in the Liverpool City Region. TriRx Speke Ltd. is the first investor and is well-positioned to further advance its capabilities by adding upstream technologies to manufacture monoclonal antibodies to an existing large-scale biotech purification facility. The current...

Read More

MedTech, Industrial Impact

QIAGEN AND HELIX PARTNER TO ADVANCE COMPANION DIAGNOSTICS FOR HEREDITARY DISEASES

QIAGEN | January 06, 2023

news image

QIAGEN recently announced an exclusive strategic partnership with Helix, a California population genomics leader, to advance companion diagnostics for hereditary diseases. The requirement for companion diagnostic devices and tests capable of detecting clinically relevant genetic abnormalities grows along with the accelerated development of precision medicines. These tests helps in making decisions by showing patients that are most likely to benefit from a specific therapeutic prod...

Read More
news image

Industrial Impact

CYBIN ANNOUNCES ADDITIONAL ADELIA MILESTONE ACHIEVEMENT

Cybin Inc. | January 28, 2022

Cybin Inc. a biotechnology company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that Adelia Therapeutics Inc. a wholly-controlled subsidiary of Cybin, has achieved the milestones identified as Y1, Q4 (iv), Y1, Q4 (v) and Y2, Q1 (vi) as contemplated by the terms of a contribution agreement dated December 4, 2020 among Cybin, Cybin Corp., Cybin US Holdings Inc. a wholly-controlled subsidiary of Cybin, and all of the previous shareholders of Adelia.
Read More

news image

Cell and Gene Therapy

BIODESIX ANNOUNCES SENIOR SECURED FINANCING AGREEMENT WITH PERCEPTIVE ADVISORS FOR UP TO $50 MILLION

Biodesix | November 17, 2022

Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, announced that it has obtained a term loan facility for up to $50 million from Perceptive Advisors, a leading healthcare investment firm focused on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare. This debt capital, which is conditioned on the Company raising at least $30 millio...

Read More
news image

Medical, Industry Outlook

TRIRX PARTNERSHIP WITH LIVERPOOL CITY REGION ADVANCES BIOTECH CAPABILITIES

PRNewswire | July 31, 2023

TriRx Pharmaceutical Services, LLC, a Contract Development and Manufacturing Organization (CDMO), welcomed the UK Government's recent announcement on England's second Investment Zone, focused on Life Sciences in the Liverpool City Region. TriRx Speke Ltd. is the first investor and is well-positioned to further advance its capabilities by adding upstream technologies to manufacture monoclonal antibodies to an existing large-scale biotech purification facility. The current...

Read More
news image

MedTech, Industrial Impact

QIAGEN AND HELIX PARTNER TO ADVANCE COMPANION DIAGNOSTICS FOR HEREDITARY DISEASES

QIAGEN | January 06, 2023

QIAGEN recently announced an exclusive strategic partnership with Helix, a California population genomics leader, to advance companion diagnostics for hereditary diseases. The requirement for companion diagnostic devices and tests capable of detecting clinically relevant genetic abnormalities grows along with the accelerated development of precision medicines. These tests helps in making decisions by showing patients that are most likely to benefit from a specific therapeutic prod...

Read More

Resources

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us